Literature DB >> 16161049

Immunocytochemistry in liquid-based cervical cytology: analysis of clinical use following a cross-sectional study.

Shaira Sahebali1, Christophe E Depuydt, Gaëlle A V Boulet, Marc Arbyn, Liliane M Moeneclaey, Annie J Vereecken, Eric A Van Marck, Johannes J Bogers.   

Abstract

Cytological screening for cervical cancer is hampered by imperfect sensitivity and low inter-observer reproducibility. Human papillomavirus (HPV) testing lacks specificity as a primary screening method. Studies indicate that immunocytochemical detection of alterations caused by HPV in the host cells can optimise screening. Here, the potential of p16(INK4a) (cyclin-dependent kinase inhibitor p16) and MIB-1 (Ki-67 proliferation marker) as adjunct molecular markers for cervical lesions was investigated in a prospective, cross-sectional study of 500 samples in the framework of opportunistic screening in Flanders, Belgium. A consecutive series of 200 samples and 100 samples from the cytological categories ASC, LSIL and HSIL were investigated. Surepath samples were interpreted according to the Bethesda 2001 reporting system. HPV testing was done with MY09/MY11 consensus PCR. Immunocytochemistry for p16(INK4a) and MIB-1 was performed with an automated staining protocol. The number of immunoreactive cells/1,000 cervical cells was assessed. There was a higher mean number of p16(INK4A) and MIB-1 immunoreactive cells/1,000 cells in HSIL (4.06 +/- 1.93 and 11.13 +/- 2.83, respectively) compared to other cytological categories. Both markers showed a large spread in counts, for all categories. In cases of HSIL without immunoreactive cells for either marker, low cellularity and long-term storage in water were often the cause of false negativity. This study confirms that positive staining for p16(INK4a) and MIB-1 is highly correlated with presence of high-grade lesions. These markers could be used as adjuncts to increase the sensitivity of cytological screening as well as the specificity of the HPV test. However, clear methodological standards are needed for optimal performance of immunocytochemistry in a clinical setting. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16161049     DOI: 10.1002/ijc.21489

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

1.  MOLECULAR MARKERS OF EARLY CERVICAL NEOPLASIA.

Authors:  Alvaro P Pinto; Christopher P Crum; Michelle S Hirsch
Journal:  Diagn Histopathol (Oxf)       Date:  2010-10-01

2.  Automated detection of dual p16/Ki67 nuclear immunoreactivity in liquid-based Pap tests for improved cervical cancer risk stratification.

Authors:  Arkadiusz Gertych; Anika O Joseph; Ann E Walts; Shikha Bose
Journal:  Ann Biomed Eng       Date:  2012-01-04       Impact factor: 3.934

3.  Utility of immunochemistry in cytology.

Authors:  Pooja Chavali; Aruna Kumari Prayaga; Ashwani Tandon; Shantveer Gurulingappa Uppin
Journal:  J Cytol       Date:  2016 Apr-Jun       Impact factor: 1.000

4.  Hybrid capture vs. PCR screening of cervical human papilloma virus infections. Cytological and histological associations in 1270 women.

Authors:  Sotirios Tsiodras; John Georgoulakis; Aikaterini Chranioti; Zanis Voulgaris; Amanda Psyrri; Angeliki Tsivilika; John Panayiotides; Petros Karakitsos
Journal:  BMC Cancer       Date:  2010-02-22       Impact factor: 4.430

Review 5.  p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis.

Authors:  I Tsoumpou; M Arbyn; M Kyrgiou; N Wentzensen; G Koliopoulos; P Martin-Hirsch; V Malamou-Mitsi; E Paraskevaidis
Journal:  Cancer Treat Rev       Date:  2009-03-03       Impact factor: 12.111

Review 6.  Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia.

Authors:  Kate Cuschieri; Nicolas Wentzensen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-10       Impact factor: 4.254

7.  Ancillary testing of liquid-based cytology specimens for identification of patients at high risk of cervical cancer.

Authors:  Takuma Fujii; Miyuki Saito; Takashi Iwata; Nobumaru Hirao; Hiroshi Nishio; Akiko Ohno; Katsumi Tsukazaki; Makio Mukai; Kaori Kameyama; Daisuke Aoki
Journal:  Virchows Arch       Date:  2008-10-21       Impact factor: 4.064

8.  Cytological Evaluation and REBA HPV-ID HPV Testing of Newly Developed Liquid-Based Cytology, EASYPREP: Comparison with SurePath.

Authors:  Youn Soo Lee; Gyungyub Gong; Jin Hee Sohn; Ki Sung Ryu; Jung Hun Lee; Shin Kwang Khang; Kyung-Ja Cho; Yong-Man Kim; Chang Suk Kang
Journal:  Korean J Pathol       Date:  2013-06-25

9.  Comparison Between Two Detection Methods for HPV16, HPV18 and P16Ink4a Biomarkers in Diagnosis of Abnormal Cervical Cytology

Authors:  Sedigheh Khazaei; Babak Izadi; Seyed Ghasem Mirbahari; Seyed Hamid Madani; Shohre Malek Khosravi; Mohsen Emami Alagha; Soraya Sajadimajd
Journal:  Asian Pac J Cancer Prev       Date:  2016-12-01

10.  The integration of HR-HPV increases the expression of cyclins A and E in cytologies with and without low-grade lesions.

Authors:  M I Zubillaga-Guerrero; B Illades-Aguiar; M A Leyva-Vazquez; E Flores-Alfaro; E Castañeda-Saucedo; J F Muñoz-Valle; L C Alarcón-Romero
Journal:  J Cytol       Date:  2013-01       Impact factor: 1.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.